JM Financial's research report onDr Reddys Labs
4QFY18 was a weak operating quarter for Dr Reddy’s with Revenues/EBITDA/PAT being 4%/22%/13% below our estimates. Revenues declined 1% YoY to INR 35.3bn mainly driven by the decline in (i) US generics (-6% YoY; -10% QoQ) due to increasing competition in key products, and, (ii) Russia (-25% YoY; -24% QoQ) due to lower off-take by channels.
OutlookHowever, reversion to mean in Russia and benefits from the ongoing cost-efficiency improvement measures moderate the extent of estimate cuts. We cut our FY19/20 EPS by 5%/4%, respectively, and arrive at a Mar’19 TP of INR 2,110 using an unchanged multiple of 18x FY20 EPS. Maintain SELL.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.